Fidson Healthcare, the leading pharmaceutical firm in Nigeria, and Jiangsu Aidea Pharmaceutical Co. Ltd (Aidea Pharma), an innovative pharmaceutical company in China, have formally inked a strategic cooperation agreement in China.
The deal will see the two companies work together to develop new pharmaceutical products. The purpose of the agreement is to promote and address medical difficulties through the use of novel pharmaceuticals, particularly in the treatment of more than 1.9 million individuals in Nigeria who are afflicted with HIV.
According to the statement that was included in the press release issued by Fidson Healthcare, the two companies came to an agreement to share and combine their respective resources, technical expertise, and positions in the market in order to collaborate on the development of projects, the expansion of markets, and other aspects by integrating their respective competitive advantages in the field of pharmaceuticals.
Both businesses have agreed to collaborate on a number of different fronts and in a variety of different ways, including but not limited to product manufacturing, marketing and sales efforts, and clinical research involving both existing products and projects in the pipeline.
During the signing event, the directors of both firms spoke about the relevance of the partnership to the growth of local pharmaceutical production in Nigeria. This was done in conjunction with the presentation of the memorandum of understanding between the two companies.
Read also: Pharmaceutical platform i’SUPPLY Secures pre-seed investment of US$1.5 million
What you need to be aware of
The relationship has the potential to serve as a significant growth engine for both firms and, more specifically, as a major contributor to the growth of pharmaceutical production in Nigeria.
Additionally, it will enhance the standard of healthcare and medical practice throughout the continent. It is anticipated that it would serve as a shining example of comprehensive collaboration between China and Nigeria in medicine.
At the moment, Fidson is the pharmaceutical company that is both the largest and the most important in Nigeria. In 2005, this business was the first in all of Sub-Saharan Africa to begin producing anti-retroviral medications for HIV patients. Within the Nigerian market, Fidson possesses a sizable sales network in addition to a broad business reach.
Aidea Pharma has its primary emphasis on the research and production of anti-HIV medications and makes use of the competitive advantages it possesses in the field of human protein.
The firm is dedicated to research and development and is currently working on constructing a full pipeline of anti-retroviral medications (ARV). Additionally, the company possesses both fundamental technical advantages and product first-mover advantages in this industry.
What Fidson had to say
According to Dr. Heliang Fu, Chairman of Aidea Pharma, who made this statement, this collaboration marked a crucial step for Aidea Pharma in its dedication to worldwide medical cooperation.
“By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients.”
Fidson’s Managing Director and CEO, Dr. Fidelis A. Ayebae, said both groups were excited about working together.
“We believe that the complementary strengths of both parties will inject new vitality into the medical field in Africa. This is also in line with our commitment “To provide better and more accessible medicines for the people of Africa.”